



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Rivaroxaban (Xarelto®)
Indication under review	Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE out of hours
Policy No:	APC 041
Date of Issue:	March 2014
Review Date:	March 2017
Policy Statement: The use of rivaroxaban for the treatment of venous thromboembolism (VTE) in patients presenting to their GP out of hours is not recommended.	
Traffic Light Status	Brown (in situations where a GP cannot refer a patient for scans and test for over 24 hours due to a patient presenting late on Friday or over a weekend)
Key Points considered: <ul style="list-style-type: none">• Warfarin remains the anticoagulant of choice for most patients with VTE.• Patients presenting out of hours with suspected VTE should be managed with the current standard treatment (low molecular weight heparin)• Rivaroxaban dosing should be modified in renal impairment. Patients presenting out of hours may not have had recent U & E tests done.• This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget	
References: Greater East Midlands Commissioning Support Unit: Prescribing and Clinical Effectiveness Bulletin Vol 7, Number 15 Aug 2013 NICE technology appraisal 287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism	
Date taken to APC:	5 th March 2014
Date Ratified by MMC on Behalf of the Board:	19 th March 2014